Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBsf Enterprise. Regulatory News (BSFA)

Share Price Information for Bsf Enterprise. (BSFA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.75
Bid: 4.50
Ask: 5.00
Change: 0.00 (0.00%)
Spread: 0.50 (11.111%)
Open: 4.75
High: 4.75
Low: 4.75
Prev. Close: 4.75
BSFA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

3D Bio-Tissues partners with cell growth company

23 Nov 2022 07:00

RNS Number : 2805H
BSF Enterprise PLC
23 November 2022
 

 23 November 2022

BSF Enterprise PLC

("BSF" or the "Company")

3D Bio-Tissues enters partnership with leading cell growth company

 

BSF (LSE:BSFA), an investment company focused on unlocking the next generation of biotech solutions and the development of lab-grown tissues, is pleased to announce that its 100% owned subsidiary, 3D Bio-Tissues Ltd (3DBT), is to partner with the growth factor company Qkine to help accelerate the creation of affordable cultivated meat.

 

Together, 3DBT and Qkine will work to optimise the effectiveness of animal-free cultures to reduce the dependence on other protein compounds, increase yields, and lower overall costs. This is expected to pave the way for advances in cellular agriculture in the UK and world-wide.

 

The collaboration will see 3DBT combine City-mix™, its animal free media supplement for culturing muscle and fat cells, with Qkine's growth enabling protein engineering technology. Qkine's technology aids the growth of stem cell culture protocols, while 3DBT's innovative macromolecular crowding technology enhances the speed of development of protein components in culture media. Together these can help reduce the production time and costs for growing cultivated meat, making it more accessible and affordable to a growing mass production market.

 

The announcement comes just days after the U.S. Food and Drug Administration (FDA) approved lab-grown meat for consumption for the first time, in relation to Upside Foods cultivated chicken. In November 2022, 3DBT also announced that it had successfully produced three small prototype fillets of cultivated meat. 3DBT now plans to unveil further larger scale prototypes and the UK's first 100% lab-grown fillet in the coming months.

Dr. Catherine Elton, CEO of Qkine commented: "We are delighted to be working with the innovative 3D Bio-Tissues team. Qkine is committed to establishing a UK-based supply chain for the cellular agriculture industry and contributing to building a more sustainable global future food system."

Che Connon, Chief Executive of 3D-Bio Tissues, said: "We look forward to partnering with Qkine, which has long been at the forefront of developing high-quality protein growth factors for research applications. Our mission is to accelerate the creation of affordable cultivated meat and we strongly believe combining 3DBT's unique food-grade City-mix™ supplements with Qkine's world-leading products can provide great strides toward reaching this goal, putting us on the path to a sustainable cultivated meat industry."

For further enquiries, please visit www.bsfenterprise.com or contact:

 

 

BSF Enterprise PLC

 

 

Via SEC Newgate below

Geoff Baker - Non-Executive Director

Che Connon - Executive Director

 

Shard Capital (Broker)

Damon Heath

0203 971 7000

SEC Newgate (Financial Communications)

Bob Huxford

Elisabeth Cowell

George Esmond

020 3757 6882

BSF@secnewgate.co.uk

 

ISIN of the Ordinary Shares is GB00BHNBDQ51

SEDOL Code is BHNBDQ5.

 

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions - using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes, as part of a radical transformation to deliver sustainable solutions across a variety of sectors.

It owns 100% of 3D Bio Tissues Ltd (3DBT), a tissue engineering with patent-protected IP that is already producing human corneas to help restore vision to millions of people. Building on this success, it aims to produce the UK's first high quality lab-grown meat from its laboratory in Newcastle the next 12 months, transforming the meat-production industry towards an ethical and sustainable practice. 

BSF aims to deliver growth to shareholders through the continued commercialisation of 3DBT's IP, which has multiple applications, as well as through M&A. It aims to acquire a suite of technologies that underpins the development of tissue templating for corneas, meat and leather, and license out the IP to manufacturers, wholesalers and distributors to help manufacture the products at scale. 

About Qkine

Qkine manufactures high-purity, animal-free growth factors, cytokines and other complex proteins. Based in Cambridge, UK, Qkine combines proprietary production processes with protein engineering technology to tackle fundamental biological and scalability challenges for the fast-growing stem cell, organoid, regenerative medicine, and cultured meat sectors. Contact the Qkine team at proteins@qkine.com for more information.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDDBDBXGDDGDD
12
Date   Source Headline
11th Apr 20247:00 amRNSSuccessful Cultivated Leather PoC Agreements
20th Mar 202412:56 pmRNSResult of Annual General Meeting
20th Mar 202410:19 amRNSUniversity Collaborations
14th Mar 20247:00 amRNSInvestor Evening
7th Mar 20247:00 amRNSBSF Enterprise and Ivy Farm Enter Partnership
29th Feb 20247:00 amRNSMoU with Sustainable Fashion Company
26th Feb 20247:27 amRNSNotice of AGM
22nd Feb 20247:00 amRNSKerato Limited - Update
15th Feb 20247:00 amRNSStrategic Update
31st Jan 20247:00 amRNSFull Year Results
8th Dec 20237:00 amRNSFOODTECH Joint Venture with CellRev
30th Nov 20233:07 pmRNSStandard form for notification of major holdings
24th Nov 20237:00 amRNS3D Bio-Tissues Product Partnership Progress
26th Oct 20237:00 amRNSNew Cornea Company & Investor Update
9th Oct 20239:34 amRNSParticipation in The ThinkEquity Conference
26th Sep 20232:32 pmRNSResults of General Meeting & Allotment of Shares
18th Sep 20237:00 amRNS3D Bio-Tissues receives EUR612,000 grant
11th Sep 20237:00 amRNSStrategic Update
7th Sep 20239:46 amRNSPublication of Prospectus & Notice of GM
17th Jul 20237:00 amRNSCity-Mix Bio-Pharmaceutical Update
3rd Jul 20239:56 amRNSOpens Office in Hong Kong
29th Jun 20237:00 amRNSInterim Results
23rd Jun 202311:30 amRNSCultivated Meat Approved for Consumption in US
8th Jun 20237:00 amRNSUS Investor Roadshow & Appointment of US IR Agency
1st Jun 20237:00 amRNSPublication of New Research
30th May 20237:00 amRNSSuccessful Cultivated Meat Test
25th May 20237:00 amRNSAdmittance to trading on the OTCQB Venture Market
22nd May 20237:00 amRNSCommercial Progress Update
15th May 20237:00 amRNSLab-Grown Leather Update and Innovation Award Win
21st Apr 20237:00 amRNSShowcase Meat Update
14th Apr 20238:00 amRNSAdmission of Placing Shares & Subscription Shares
12th Apr 20233:35 pmRNSUpdate to Oversubscribed £2.9 million fundraise
29th Mar 20234:35 pmRNSPrice Monitoring Extension
29th Mar 20237:00 amRNSOversubscribed £2.9 million fundraise
15th Mar 202311:59 amRNSResult of Annual General Meeting
15th Mar 20237:00 amRNSAGM Statement
9th Mar 20238:53 amRNSApplication for Trading on US OTCQB Venture Market
6th Mar 20237:00 amRNSCity-Mix Commercial Progress Update
20th Feb 20233:00 pmRNSNotice of AGM
10th Feb 20237:00 amRNSAllotment of shares
1st Feb 20234:40 pmRNSSecond Price Monitoring Extn
1st Feb 20234:35 pmRNSPrice Monitoring Extension
1st Feb 20232:05 pmRNSSecond Price Monitoring Extn
1st Feb 20232:00 pmRNSPrice Monitoring Extension
1st Feb 20237:00 amRNSUK’s First Fillet of Cultivated Meat Produced
31st Jan 20234:36 pmRNSAnnual Report and Financial Statements
19th Dec 20227:00 amRNS3D Bio-Tissues enters partnership with New Harvest
23rd Nov 20224:40 pmRNSSecond Price Monitoring Extn
23rd Nov 20224:36 pmRNSPrice Monitoring Extension
23rd Nov 20227:00 amRNS3D Bio-Tissues partners with cell growth company
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.